Portfolio of Glaucoma Products

Aerie has three product candidates in late Phase 2 clinical trials, and one follow-on 'Dual Action' product in our pipeline that is currently in a preclinical stage. Our clinical-stage product candidates have demonstrated reductions of IOP in completed Phase 2 studies and have also displayed favorable safety and tolerability profiles. The three clinical stage products are highlighted below.

AR-12286 Rho Kinase Inhibitor

Nearly half of all glaucoma patients require a second drug, in large part due to insufficient efficacy of their first-line drugs, which are predominantly prostaglandin agonists. The most commonly used second-line drugs currently on the market are approximately two decades old, and represent weaker therapies with multiple daily dosing.

AR-12286 has the potential to be the preferred choice for second-line therapy. It is the first drug to lower eye pressure by relaxing and clearing the eye's primary drain, known as the trabecular meshwork. It addresses the insufficient efficacy of first-line drugs with a tolerability profile and dosing frequency that is superior to current second-line drug choices.

PG286 Fixed Combination with Travoprost

This exciting product candidate is targeted to be the first prostaglandin fixed combination product marketed in the U.S., and would be the first glaucoma therapy to lower eye pressure by increasing fluid outflow through both of the eye's drains. PG286 combines Aerie's drug AR-12286 with travoprost, a currently marketed prostaglandin agonist. It is expected to enter the market as a first- and/or second-line drug.

PG286 has potentially the highest effectiveness of all currently marketed monotherapy and combination therapy products.

AR-13324 Dual Action

AR-13324 represents a new drug class discovered at Aerie. It increases fluid outflow through the primary drain in the eye while also reducing inflow. It acts through the inhibition of both Rho Kinase and the Norepinephrine Transporter.